StreetInsider.com News Articles

Oppenheimer Starts Prime Medicine (PRME) at Outperform

Thu, 12 Mar 2026 06:20:12 -0400

Oppenheimer analyst Kostas Biliouris initiates coverage on Prime Medicine (NASDAQ: PRME) with a Outperform rating and a price target of $11.00.

For an analyst ratings summary and ratings history on Prime Medicine click here. For more ratings news on Prime Medicine click here.

Shares of Prime Medicine closed at $3.83 yesterday.

Form EFFECT Prime Medicine, Inc.

Thu, 05 Mar 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260305/26114550.html

Form EFFECT Prime Medicine, Inc.

Thu, 05 Mar 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260305/26114550.html

Prime Medicine (PRME) Reiterated at Market Outperform by Citizens on AATD, WD Interest

Wed, 04 Mar 2026 04:51:48 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $6.00 price target on Prime Medicine (NASDAQ: PRME).

The analyst commented, "Prime had previously indicated that it would explore options for the continued clinical development of PM359 external to the company and cease further efforts in X-linked CGD. Following promising proof-of-concept in two patients and the emergence of the N-of-1/plausible mechanism FDA draft guidance, the thinking around PM359 evolved. Based on the promising data to date, including the demonstration of improvement in clinical outcomes or course, and the clear mechanism PM359 may be an ideal rare disease candidate for this regulatory

Form S-8 Prime Medicine, Inc.

Tue, 03 Mar 2026 08:41:00 -0400

si-local-file:///var/storage/secattach/20260303/26097304.html

Form S-8 Prime Medicine, Inc.

Tue, 03 Mar 2026 08:41:00 -0400

si-local-file:///var/storage/secattach/20260303/26097304.html

Form POS AM Prime Medicine, Inc.

Tue, 03 Mar 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260303/26097224.html

Form POS AM Prime Medicine, Inc.

Tue, 03 Mar 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260303/26097224.html

Form 10-K Prime Medicine, Inc. For: Dec 31

Tue, 03 Mar 2026 08:20:00 -0400

si-local-file:///var/storage/secattach/20260303/26097062.html

Form 10-K Prime Medicine, Inc. For: Dec 31

Tue, 03 Mar 2026 08:20:00 -0400

si-local-file:///var/storage/secattach/20260303/26097062.html

Form POSASR Prime Medicine, Inc.

Tue, 03 Mar 2026 08:14:00 -0400

si-local-file:///var/storage/secattach/20260303/26097018.html

Form POSASR Prime Medicine, Inc.

Tue, 03 Mar 2026 08:14:00 -0400

si-local-file:///var/storage/secattach/20260303/26097018.html

Form 8-K Prime Medicine, Inc. For: Mar 03

Tue, 03 Mar 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260303/26096910.html

Form 8-K Prime Medicine, Inc. For: Mar 03

Tue, 03 Mar 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260303/26096910.html

Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

Tue, 03 Mar 2026 08:00:00 -0400

-- On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 --

-- Ongoing engagement with FDA for PM359 in CGD; plan to submit BLA following final alignment --

-- Prime Medicine reported cash, cash equivalents, investments, and restricted cash of $191M providing cash runway into 2027 --

CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative

Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates

Tue, 03 Mar 2026 08:00:00 -0400

-- On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 --

-- Ongoing engagement with FDA for PM359 in CGD; plan to submit BLA following final alignment --

-- Prime Medicine reported cash, cash equivalents, investments, and restricted cash of $191M providing cash runway into 2027 --

CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative

Prime Drink Group Announces Management Change

Fri, 27 Feb 2026 17:15:00 -0400

MONTRÉAL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) is pleased to announce the appointment of Germain Turpin as Interim President and Chief Executive Officer of the Company. Mr. Turpin succeeds Alexandre Côté, who will step down from his position on February 28, 2026, while remaining on the Board of Directors and retaining responsibility for special projects.

Germain Turpin has over 20 years of experience in the water industry in Québec. Former owner of two of the water assets now held by the Company, he will leverage

Prime Drink Group Announces Management Change

Fri, 27 Feb 2026 17:15:00 -0400

Germain Turpin has over 20 years of experience in the water industry in Québec. Former owner of two of the water assets now held by the Company, he will leverage

Prime Drink Group Announces Management Change

Fri, 27 Feb 2026 17:15:00 -0400

Germain Turpin has over 20 years of experience in the water industry in Québec. Former owner of two of the water assets now held by the Company, he will leverage

Prime Drink Group Announces Management Change

Fri, 27 Feb 2026 17:15:00 -0400

Germain Turpin has over 20 years of experience in the water industry in Québec. Former owner of two of the water assets now held by the Company, he will leverage

Form 4 Prime Medicine, Inc. For: Feb 26 Filed by: Reine Allan

Fri, 27 Feb 2026 16:53:00 -0400

si-local-file:///var/storage/secattach/20260227/26083088.html

Form 4 Prime Medicine, Inc. For: Feb 26 Filed by: Reine Allan

Fri, 27 Feb 2026 16:53:00 -0400

si-local-file:///var/storage/secattach/20260227/26083088.html

Prime Medicine to Participate in Upcoming Investor Conferences

Wed, 25 Feb 2026 08:00:00 -0400

CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in three upcoming conferences:

TD Cowen 46^th Annual Health Care Conference: Fireside chat on Wednesday, March 4, 2026, at 1:10 p.m. ET in Boston, MA.
2026 Jefferies Biotech on the Beach Summit: Company management will host 1x1 meetings on Tuesday, March 10, 2026, in Miami Beach, FL.
The Citizens Life Sciences Conference: Fireside chat on Wednesday, March 11, 2026, at 2:15 p.m. ET

Prime Medicine to Participate in Upcoming Investor Conferences

Wed, 25 Feb 2026 08:00:00 -0400

TD Cowen 46^th Annual Health Care Conference: Fireside chat on Wednesday, March 4, 2026, at 1:10 p.m. ET in Boston, MA.
2026 Jefferies Biotech on the Beach Summit: Company management will host 1x1 meetings on Tuesday, March 10, 2026, in Miami Beach, FL.
The Citizens Life Sciences Conference: Fireside chat on Wednesday, March 11, 2026, at 2:15 p.m. ET

Form 4 Prime Medicine, Inc. For: Feb 23 Filed by: LEE ANN L.

Tue, 24 Feb 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260224/26052895.html